A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.
Keep Reading
HSUHK’s award-winning system shows how AI, drones and AR can cut training time, reduce errors and reshape warehouse operations
Updated
March 30, 2026 2:29 PM
Dji Mavic Mini 2 drone. PHOTO: ADOBE STOCK
As global tech ecosystems become more interconnected, the ability to move innovation across borders is becoming just as important as building it. A new partnership between MTR Lab, the investment arm of MTR Corporation and ZGC Science City Ltd, a government-backed technology ecosystem based in Beijing’s Haidian district, reflects this shift.
At its core, the collaboration is designed to connect high-potential Chinese startups with global capital, real-world deployment opportunities and international markets. It focuses on sectors like AI, robotics, smart mobility and sustainable urban development—areas where China already has strong technical depth but where scaling beyond domestic markets can be more complex.
This is where the partnership begins to matter. ZGC Science City sits at the center of one of China’s most concentrated innovation clusters, with thousands of AI companies and a growing base of specialised and high-growth firms. MTR Lab, on the other hand, brings access to international markets, industry networks and practical deployment environments tied to infrastructure, transport and urban systems. Together, they are attempting to bridge a familiar gap: turning local innovation into globally relevant products.
In practice, the model is straightforward. ZGC Science City will introduce MTR Lab to startups working in priority sectors, creating a pipeline for potential investment and collaboration. From there, MTR Lab can support these companies through funding, pilot projects and access to overseas markets. The idea is not just to invest, but to help startups test and apply their technologies in real-world settings, particularly in complex urban environments.
The timing is notable. China’s AI and deep tech ecosystem has expanded rapidly, with thousands of companies contributing to advancements in automation, smart infrastructure and sustainability. At the same time, global demand for these technologies is rising, especially as cities look for more efficient and scalable solutions. Yet, moving from innovation to adoption often requires cross-border coordination—something individual startups may struggle to navigate alone.
This partnership also builds on a broader pattern. Corporate venture arms like MTR Lab are increasingly positioning themselves not just as investors, but as connectors between markets. By combining capital with access to infrastructure and deployment scenarios, they offer startups a way to move faster from development to real-world use. For ZGC Science City, the collaboration adds an international layer to its ecosystem, helping local companies extend beyond domestic growth.
What emerges is a model that goes beyond a typical investment announcement. It reflects a growing recognition that innovation today is rarely confined to one geography. Technologies may be developed in one ecosystem, refined in another and scaled globally through partnerships like this.
As cross-border collaboration becomes more central to how startups grow, partnerships like the one between MTR Lab and ZGC Science City point to a more connected innovation landscape—one where access, not just invention, defines success.